Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective lifted by research analysts at The Goldman Sachs Group from $60.00 to $75.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target suggests a potential upside of 18.64% from the stock’s current price.

Other equities analysts have also issued research reports about the company. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 23rd. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Finally, Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $68.00.

Kiniksa Pharmaceuticals International Trading Up 1.2%

Shares of KNSA stock traded up $0.78 during trading hours on Thursday, reaching $63.22. 71,645 shares of the company’s stock were exchanged, compared to its average volume of 711,938. The stock has a market cap of $4.86 billion, a PE ratio of 70.23 and a beta of 0.07. The stock’s fifty day moving average price is $56.66 and its two-hundred day moving average price is $49.73. Kiniksa Pharmaceuticals International has a 1 year low of $26.27 and a 1 year high of $67.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. Kiniksa Pharmaceuticals International’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.11 EPS. On average, equities analysts expect that Kiniksa Pharmaceuticals International will post 1.25 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Barry D. Quart sold 13,099 shares of the stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total value of $656,259.90. Following the completion of the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This represents a 51.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of Kiniksa Pharmaceuticals International stock in a transaction on Friday, May 1st. The stock was sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the sale, the insider directly owned 65,623 shares in the company, valued at approximately $3,524,611.33. This trade represents a 47.10% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 628,427 shares of company stock worth $32,833,228. Corporate insiders own 51.98% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds have recently bought and sold shares of KNSA. Mark Sheptoff Financial Planning LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock valued at $674,000 after buying an additional 250 shares in the last quarter. Mariner LLC lifted its stake in Kiniksa Pharmaceuticals International by 2.0% during the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock worth $558,000 after acquiring an additional 266 shares in the last quarter. First Trust Advisors LP lifted its stake in Kiniksa Pharmaceuticals International by 3.1% during the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after acquiring an additional 293 shares in the last quarter. Virtus Investment Advisers LLC boosted its holdings in Kiniksa Pharmaceuticals International by 2.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after acquiring an additional 406 shares during the period. Finally, Mercer Global Advisors Inc. ADV boosted its holdings in Kiniksa Pharmaceuticals International by 7.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after acquiring an additional 508 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.